Protein biomarkers for assessing Inflammatory Bowel Disease (IBD) treatment efficiency

Evaluation of a new method of noninvasive material collection for protein biomarker detection as an approach to assessing inflammatory bowel disease treatment efficiency.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN17818329

Enrollment

200

Registered

2015-01-12

Start date

2013-01-16

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) Digestive System Inflammatory bowel disease

Interventions

Although the study is basically observational, non-invasive collection (self-collection by study participants) of diagnostically informative samples is undertaken.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with active IBD requiring conservative treatment; 2. Patients with IBD in remission 3. Patients with IBS 4. Healthy volunteers (a smaller group)

Exclusion criteria

Exclusion criteria: 1. Concomitant colorectal disease other than IBD or IBS 2. Extensive colorectal surgery in the past

Design outcomes

Primary

Measure	Time frame
1. Confirmation of sample collection method acceptance by patients 2. Confirmation of high quality of the collected material 3. Confirmation of the validity of biomarker quantification in the collected material for diagnostic and monitoring purposes	—

Secondary

Measure	Time frame
1. Selection of optimal biomarkers for IBD diagnosis 2. Selection of optimal biomarkers for IBD therapy efficiency assessment	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026